Autopsy report · NCT00573755

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

“lack of participant accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 4 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

anastrozole; exemestane; letrozole; sorafenib tosylate; placebo

Participants

4

Sites

3

Countries

United States

Trials that died the same way

• 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
  “Low participant accrual” (85% match in meaning)
• A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer
  “Challenges to participant accrual” (83% match in meaning)
• Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
  “Lack of accrual” (81% match in meaning)
• A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
  “0 participant accrual” (81% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.